Europe Gene Therapy Market was valued at USD 1.1 Billion in 2022 and is projected to reach USD 1.8 Billion by 2030, growing at a CAGR of 6.4% from 2024 to 2030.
Gene therapy is revolutionizing healthcare in Europe, offering potential cures for genetic disorders by modifying genes at their source. The European gene therapy market was valued at approximately $2 billion in 2023 and is projected to reach $6.02 billion by 2028, reflecting a compound annual growth rate (CAGR) of 24.6%. citeturn0search2 **Types of Gene Therapy in Europe** - **Viral Vectors**: These are the most commonly used tools in gene therapy, leveraging viruses' natural ability to deliver genetic material into cells. Types include: - *Retroviruses*: Integrate their genetic material into the host genome, ensuring long-term expression. - *Adenoviruses*: Deliver genes without integrating into the host DNA, reducing the risk of insertional mutagenesis. - *Adeno-associated Viruses (AAVs)*: Preferred for their low pathogenicity and ability to infect both dividing and non-dividing cells. - **Non-Viral Vectors**: These methods involve physical or chemical techniques to introduce genetic material into cells, such as: - *Plasmid DNA*: Circular DNA molecules used to transfer genes without viral components. - *Electroporation*: Uses electrical pulses to create temporary pores in cell membranes, facilitating gene entry. - *Lipofection*: Employs lipid-based carriers to encapsulate and deliver genetic material into cells. **Industry Requirements and Challenges** Despite the promising growth, the European gene therapy sector faces several challenges: - **Regulatory Landscape**: The European Medicines Agency (EMA) oversees gene therapy approvals, ensuring treatments meet rigorous safety and efficacy standards. However, the complex regulatory framework can lead to delays in bringing therapies to market. citeturn0search3 - **Funding Disparities**: European cell and gene therapy developers often struggle with limited funding compared to their North American counterparts. In the first three quarters of 2024, U.S. companies secured $11.8 billion, nearly six times the $2 billion raised in Europe, equating to almost three times more funding per developer. citeturn0search0 - **Manufacturing and Scalability**: Producing gene therapies requires sophisticated facilities and expertise. Innovations like Cellares' "Cell Shuttle" aim to automate production, reducing labor and space requirements, thereby increasing efficiency. citeturn0news25 - **Reimbursement and Accessibility**: The high cost of gene therapies poses challenges for healthcare systems. For instance, the UK's National Health Service (NHS) negotiated a discount for the $1.7 million CRISPR-based therapy, Casgevy, to treat beta-thalassemia, highlighting efforts to make such treatments accessible. citeturn0news29 In my experience attending industry conferences, stakeholders frequently discuss the need for harmonized regulations and increased investment to foster innovation in Europe's gene therapy landscape. Addressing these challenges is crucial for the continued growth and success of gene therapy in Europe.
Get an In-Depth Research Analysis of the Europe Gene Therapy Market Size And Forecast [2025-2032]
Avalanche Bio
Advantagene
Celladon
Sangamo
Bluebird Bio
Vical Inc.
Dimension Therapeutics
Spark Therapeutics
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Europe Gene Therapy Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Europe Gene Therapy Market
Ex vivo gene therapy
In vivo gene therapy
Oncology
Genetic Disorders
Cardiovascular Diseases
Infectious Diseases
Neurological Disorders
Viral Vectors
Non-viral Vectors
Hospitals
Research Institutions
Biopharmaceutical Companies
CRISPR
TALEN
Zinc Finger Nucleases (ZFNs)
RNA Interference
US (United States, US and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Gene Therapy Market Research Analysis
1. Introduction of the Europe Gene Therapy Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Europe Gene Therapy Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Europe Gene Therapy Market, By Type
6. Europe Gene Therapy Market, By Application
7. Europe Gene Therapy Market, By Geography
US
Europe
Asia Pacific
Rest of the World
8. Europe Gene Therapy Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Europe Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/